The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Mobile Phones are a very important part of our daily life. From calling and messaging…
Mongolian parliament has appointed the Uchral Nyam-Osor as the country' new Prime Minister. With this…
To boost export potential of Indian textile industries Ministry of Textiles has extended the RoSCTL…
From the April 1st fuel stations across the country are now supplying that petrol which…
The Ministry of Education has granted the 'deemed to be university’ status to National Council…
India's Gaganyaan Mission have begun the unique experiment which is called Mission Mitra in the…